EpiCept Receives Permission to File Ceplene NDA

EpiCept Corporation announced that the U.S. Food and Drug Administration indicated that the Company has the necessary pivotal data to file a New Drug Application (NDA) for Ceplene (histamine dihydrochloride) in conjunction with interleukin-2 (IL-2) as a remission maintenance treatment of acute myeloid leukemia (AML).
centredaily.com